Last reviewed · How we verify
MIYAIRI 588
At a glance
| Generic name | MIYAIRI 588 |
|---|---|
| Sponsor | China Medical University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (PHASE1)
- PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) (NA)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (PHASE3)
- Clostridium Butyricum in Stenosing Crohn's Desease (PHASE1, PHASE2)
- Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (PHASE2)
- CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (PHASE1)
- Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIYAIRI 588 CI brief — competitive landscape report
- MIYAIRI 588 updates RSS · CI watch RSS
- China Medical University Hospital portfolio CI